It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Leucyl-tRNA synthetase (LARS) is an enzyme that catalyses the ligation of leucine with leucine tRNA. LARS is also essential to sensitize the intracellular leucine concentration to the mammalian target of rapamycin complex 1 (mTORC1) activation. Biallelic mutation in the LARS gene causes infantile liver failure syndrome type 1 (ILFS1), which is characterized by acute liver failure, anaemia, and neurological disorders, including microcephaly and seizures. However, the molecular mechanism underlying ILFS1 under LARS deficiency has been elusive. Here, we generated Lars deficient (larsb−/−) zebrafish that showed progressive liver failure and anaemia, resulting in early lethality within 12 days post fertilization. The atg5-morpholino knockdown and bafilomycin treatment partially improved the size of the liver and survival rate in larsb−/− zebrafish. These findings indicate the involvement of autophagy in the pathogenesis of larsb−/− zebrafish. Indeed, excessive autophagy activation was observed in larsb−/− zebrafish. Therefore, our data clarify a mechanistic link between LARS and autophagy in vivo. Furthermore, autophagy regulation by LARS could lead to development of new therapeutics for IFLS1.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Oita University Faculty of Medicine, Department of Cell Biology, Yufu, Japan (GRID:grid.412334.3) (ISNI:0000 0001 0665 3553); Oita University Faculty of Medicine, Department of Pediatrics, Yufu, Japan (GRID:grid.412334.3) (ISNI:0000 0001 0665 3553)
2 Aichi Medical University, Department of Neuropathology, Institute for Medical Science of Aging, Aichi, Japan (GRID:grid.411234.1) (ISNI:0000 0001 0727 1557)
3 Oita University Faculty of Medicine, Department of Cell Biology, Yufu, Japan (GRID:grid.412334.3) (ISNI:0000 0001 0665 3553)
4 Oita University Faculty of Medicine, Department of Pediatrics, Yufu, Japan (GRID:grid.412334.3) (ISNI:0000 0001 0665 3553)
5 Oita University Faculty of Medicine, Department of Neurophysiology, Yufu, Japan (GRID:grid.412334.3) (ISNI:0000 0001 0665 3553)
6 Osaka University, Division of Cellular and Molecular Biology, Department of Homeostatic Regulation, Research Institute for Microbial Diseases, Osaka, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)